Assignee
ALEXION PHARMA INC
US·162 granted patents·162 pending applications·2,286 citations·filing 1994–2025
Top patents by PatentIndex Score
324 records- 0199US9206251B2Nucleic acids encoding anti-C5 antibodies having improved pharmacokineticsALEXION PHARMA INC·Filed 2015·Granted Dec 8, 2015·36 cites·36 claims
- 0299US9107861B1Methods of treating C5 mediated complement-associated conditions with anti-C5 antibodies having improved pharmacokineticsALEXION PHARMA INC·Filed 2015·Granted Aug 18, 2015·58 cites·18 claims
- 0399US9079949B1Anti-C5 antibodies having improved pharmacokineticsALEXION PHARMA INC·Filed 2015·Granted Jul 14, 2015·182 cites·20 claims
- 0498US11434280B2Anti-C5 antibodies having improved pharmacokineticsALEXION PHARMA INC·Filed 2020·Granted Sep 6, 2022·10 cites·18 claims
- 0598US9663574B2Anti-C5 antibodies having improved pharmacokineticsALEXION PHARMA INC·Filed 2016·Granted May 30, 2017·24 cites·10 claims
- 0697US10584164B2Methods of treating atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria with anti-C5 antibodiesALEXION PHARMA INC·Filed 2019·Granted Mar 10, 2020·11 cites·10 claims
- 0797US10227400B2Methods of treating atypical hemolytic uremic syndrome with anti-C5 antibodiesALEXION PHARMA INC·Filed 2017·Granted Mar 12, 2019·14 cites·7 claims
- 0897US9803007B1Anti-C5 antibodies having improved pharmacokineticsALEXION PHARMA INC·Filed 2017·Granted Oct 31, 2017·14 cites·7 claims
- 0997US9371377B2Anti-C5 antibodies having improved pharmacokineticsALEXION PHARMA INC·Filed 2015·Granted Jun 21, 2016·22 cites·17 claims
- 1096US9718880B2Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complementALEXION PHARMA INC·Filed 2016·Granted Aug 1, 2017·17 cites·3 claims
- 1196US7393648B2Hybrid antibodiesALEXION PHARMA INC·Filed 2003·Granted Jul 1, 2008·86 cites·15 claims
- 1296US6355245B1C5-specific antibodies for the treatment of inflammatory diseasesALEXION PHARMA INC·Filed 1995·Granted Mar 12, 2002·465 cites·23 claims
- 1395US10703809B1Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complementALEXION PHARMA INC·Filed 2020·Granted Jul 7, 2020·3 cites·29 claims
- 1495US9732149B2Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complementALEXION PHARMA INC·Filed 2016·Granted Aug 15, 2017·15 cites·1 claims
- 1595US9725504B2Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complementALEXION PHARMA INC·Filed 2016·Granted Aug 8, 2017·14 cites·10 claims
- 1695US7435412B2Chronic lymphocytic leukemia cell lineALEXION PHARMA INC·Filed 2003·Granted Oct 14, 2008·34 cites·15 claims
- 1794US10954503B2Antidotes for factor Xa inhibitors and methods of using the sameALEXION PHARMA INC·Filed 2019·Granted Mar 23, 2021·4 cites·12 claims
- 1894US10954504B2Preparation of factor Xa derivativesALEXION PHARMA INC·Filed 2020·Granted Mar 23, 2021·4 cites·14 claims
- 1994US9494601B2Atypical hemolytic uremic syndrome (AHUS) biomarker proteinsALEXION PHARMA INC·Filed 2016·Granted Nov 15, 2016·14 cites·19 claims
- 2094US9221901B2Methods of treating complement-associated disorders with anti-C5a antibodiesALEXION PHARMA INC·Filed 2015·Granted Dec 29, 2015·11 cites·16 claims
- 2194US7408041B2Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereofALEXION PHARMA INC·Filed 2004·Granted Aug 5, 2008·39 cites·16 claims
- 2293US9771418B2Methods for treating complement-associated disordersALEXION PHARMA INC·Filed 2016·Granted Sep 26, 2017·8 cites·4 claims
- 2393US9658236B2Atypical hemolytic uremic syndrome (aHUS) biomarker proteinsALEXION PHARMA INC·Filed 2016·Granted May 23, 2017·11 cites·11 claims
- 2493US9371378B1Anti-C5a antibodiesALEXION PHARMA INC·Filed 2016·Granted Jun 21, 2016·7 cites·10 claims
- 2593US7396917B2Rationally designed antibodiesALEXION PHARMA INC·Filed 2002·Granted Jul 8, 2008·46 cites·65 claims
- 2693US7306906B2Engineered templates and their use in single primer amplificationALEXION PHARMA INC·Filed 2002·Granted Dec 11, 2007·123 cites·28 claims
- 2793US6982323B1Chimeric proteins for diagnosis and treatment of diabetesALEXION PHARMA INC·Filed 2000·Granted Jan 3, 2006·70 cites·8 claims
- 2893US6074642AUse of antibodies specific to human complement component C5 for the treatment of glomerulonephritisALEXION PHARMA INC·Filed 1994·Granted Jun 13, 2000·117 cites·5 claims
- 2992US10590189B2Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complementALEXION PHARMA INC·Filed 2017·Granted Mar 17, 2020·7 cites·8 claims
- 3092US9352035B2High concentration antibody formulationsALEXION PHARMA INC·Filed 2013·Granted May 31, 2016·20 cites·22 claims
- 3192US6338820B1Apparatus for performing assays at reaction sitesALEXION PHARMA INC·Filed 1998·Granted Jan 15, 2002·96 cites·52 claims
- 3291US12012448B2High concentration anti-C5 antibody formulationsALEXION PHARMA INC·Filed 2022·Granted Jun 18, 2024·4 cites·13 claims
- 3391US9409980B1Methods for treating patients with complement-associated disorders with high concentration formulations of anti-C5 antibodiesALEXION PHARMA INC·Filed 2016·Granted Aug 9, 2016·11 cites·17 claims
- 3491US9309310B2Nucleic acids encoding anti-C5a antibodiesALEXION PHARMA INC·Filed 2015·Granted Apr 12, 2016·7 cites·20 claims
- 3591US7915000B2Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereofALEXION PHARMA INC·Filed 2007·Granted Mar 29, 2011·11 cites·9 claims
- 3691USRE41365ENested oligonucleotides containing a hairpin for nucleic acid amplificationALEXION PHARMA INC·Filed 2009·Granted Jun 1, 2010·15 cites·38 claims
- 3791US7598353B2Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereofALEXION PHARMA INC·Filed 2008·Granted Oct 6, 2009·10 cites·13 claims
- 3890US12221473B2Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereofALEXION PHARMA INC·Filed 2022·Granted Feb 11, 2025·1 cites·13 claims
- 3990US11807678B2Methods and compositions for treating complement-associated disordersALEXION PHARMA INC·Filed 2019·Granted Nov 7, 2023·2 cites·3 claims
- 4090US7279158B2Methods for the treatment of inflammatory joint diseaseALEXION PHARMA INC·Filed 2005·Granted Oct 9, 2007·18 cites·17 claims
- 4190US2025092123A1Methods and compositions for treating complement-associated disordersALEXION PHARMA INC·Filed 2024·Application pending·0 cites
- 4289US11446300B2Cerdulatinib for treating hematological cancersALEXION PHARMA INC·Filed 2020·Granted Sep 20, 2022·3 cites·20 claims
- 4389US10577612B1Compositions and methods relating to genomic modifications in avian primordial germ cellsALEXION PHARMA INC·Filed 2017·Granted Mar 3, 2020·4 cites·17 claims
- 4489US9556263B2Methods for treating atypical hemolytic uremic syndrome with high concentration formulations of anti-C5 antibodiesALEXION PHARMA INC·Filed 2016·Granted Jan 31, 2017·7 cites·14 claims
- 4589US9469690B2Methods of treating complement-associated disorders with anti-C5a antibodiesALEXION PHARMA INC·Filed 2016·Granted Oct 18, 2016·4 cites·14 claims
- 4689US9434784B1Nucleic acids encodng anti-C5A antibodiesALEXION PHARMA INC·Filed 2016·Granted Sep 6, 2016·4 cites·27 claims
- 4789US2025163399A1Lyophilized formulations for factor xa antidoteALEXION PHARMA INC·Filed 2024·Application pending·0 cites
- 4889US2024141024A1Anti-c5 antibodies having improved pharmacokineticsALEXION PHARMA INC·Filed 2023·Application pending·0 cites
- 4988US12128101B2Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS)ALEXION PHARMA INC·Filed 2018·Granted Oct 29, 2024·5 cites·12 claims
- 5088US9908932B2Methods of shifting an isoelectric profile of a protein product and uses thereofALEXION PHARMA INC·Filed 2015·Granted Mar 6, 2018·13 cites·16 claims
Showing the top 50 of 324 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when ALEXION PHARMA INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →